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1 INTRODUCTION
CANOMAD is a rare syndrome encompassing chronic ataxic neuropa-
thy, ophthalmoplegia, IgM paraprotein, cold agglutinins and disialosyl
antibodies [1,2]. We present a case of acute craniobulbar palsy associ-
ated with COVID-19 in which the combination of an established IgM
paraprotein and the later emergence of a typical and persistent gan-
glioside antibody profile ultimately revealed a diagnosis of CANOMAD
syndrome.We review the clinical presentation, diagnosticwork-up and
current treatment.
2 CASE PRESENTATION
A 61-year-old right-handed male presented with a 24-h history
of altered speech, diplopia, facial weakness and dysphagia pre-
ceded by 4 days of symptoms consistent with COVID-19. His
background included a 3-year history of Waldenström’s macroglob-
ulinaemia (WM)—MYD88 positive, IgM kappa paraproteinaemia
4g/L—and a sensory peripheral neuropathy; presumed related to the
monoclonal gammopathy. His presenting neuropathy included sub-
jectively reduced sensation in a stocking distribution bilaterally and
mild gait ataxia. Examination findings at the point of diagnosis included
global areflexia, impaired vibration sense throughout the lower limbs
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with difficulty in tandem walking and preserved limb power. He was
able to walk unaided with an unlimited exercise tolerance. Nerve con-
duction studies revealed evidence of a large fibre sensory and motor
peripheral neuropathy, with mild slowing and prolonged distal motor
latencies but without reaching electrodiagnostic criteria for demyeli-
nation. He received four cycles of rituximab at diagnosis of WM for
the neuropathy and remained stable for over 2 years. However, in the
preceding 5 months to admission he reported progressive symptoms
of gait ataxia and new reduced grip strength.
Admission vital signs were stable. Cranial nerve examination
revealed a right-sided ptosis, complex ophthalmoplegia, facial diplegia,
poor palatal lift, tongue weakness and dysarthria. Limb examination
demonstratedwidespreadmild proximal weakness, areflexia, impaired
vibration throughout both legs and proprioception loss to the ankles.
Nasopharyngeal swab subsequently confirmed SARS-CoV-2 infection
by RT-PCR, although chest X-ray was normal. Blood tests revealed a
lymphopaenia (0.96× 109 L), C-reactive protein of 9mg/ml and normal
renal function. Cold agglutinins were identified and total IgM level was
7.51 g/L (0.35–2.42). Further blood tests were unremarkable, includ-
ing HbA1C, plasma viscosity, creatine kinase, vitamin B12, folate, thy-
roid stimulating hormone, anti-nuclear antibodies, complements, anti-
neutrophil cytoplasmic antibodies, hepatitis B and C serology, HIV,
acetylcholine receptor antibodies and anti-myelin associated glycopro-
tein (MAG) antibodies. Magnetic resonance imaging (MRI) of the brain
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F IGURE 1 Clinical event timeline and estimation of functional neurological disability (neurological disability based on authors interpretation
of subjective and objectivemarkers of neurological function throughout disease course from presentation). Onset and diagnosis of neuropathy
with sensory symptoms predominantly affecting the feet (a); bonemarrow biopsy confirmingWM (b), with rituximab treatment given 1month
later (c); progressive deterioration of sensory symptoms in feet, unsteady gait andweakness of grip strength (d); hospital admission with
COVID-19 and craniobulbar relapse treated with IVIg (e); diagnosis of CANOMAD and follow-up demonstrating resolution of craniobulbar
symptoms, marked improvement in motor function andmild residual sensory ataxia (f). Extent of sensory andmotor involvement shown in blue
and red, respectively
was normal. Cerebrospinal fluid analysis revealed a mildly elevated
proteinof 0.84g/L (<0.4) but noorganism, cells or abnormal findingson
cytology.
Twenty-four hours later, the patient’s respiratory condition dete-
riorated with radiological evidence of airspace consolidation. Dex-
amethasone and Remdesivir were commenced for severe COVID-19
and he required noninvasive ventilation. Neurophysiological studies
demonstrated evidence of demyelinationwithmotor conduction block,
prolonged distal motor latencies and reduced conduction velocities.
Intravenous immunoglobulin (IVIg), 0.4 g/kg/day for 5 days, was admin-
istered for a presumptive diagnosis of Guillain–Barré syndrome (GBS).
One week following IVIg treatment, there was complete resolution of
ophthalmoparesis, facial diplegia and limb weakness with improving
bulbar function. Eleven days into admission, respiratory function had
normalised and the patient was discharged home.
Pre-IVIg anti-ganglioside antibody panel subsequently demon-
strated IgM titres of GD1a, GD1b and Gq1b all >1000 (<500) per-
sisting at 2-month follow-up, corroborating a unifying diagnosis of
CANOMAD. Repeat examination revealed a persistent sensory ataxia,
butmobility had returned to baseline level. Figure 1 illustrates the clin-
ical trajectory.
3 DISCUSSION
CANOMAD is characterised by a chronic neuropathy with sensory
ataxia and variable motor weakness, typically involving the ocular and
bulbar muscles, occurring in the presence of monoclonal IgM directed
against disialosyl ganglioside epitopes (GD1b, GD3, GT1b and GQ1b).
Overt haematological malignancy is seen in around one-third. The
associated neuropathy is often demyelinating, although not all neu-
rophysiological testing will reveal this, such as in our case on initial
testing. Ataxic neuropathy is frequently thedominant symptom, poten-
tially causing severe disability. Disease trajectory is variable, typically
extending over decades, with progression in two-thirds and a third
relapsing-remitting [3]. Misdiagnosis is common, in part because fewer
than half of the patients exhibit the full spectrum of clinical features,
ultimately delaying appropriate treatment. Craniobulbar manifesta-
tions may be intermittent or persistent and often herald relapse, rais-
ing suspicion for CANOMAD in patients with an IgM paraprotein and
undifferentiated neuropathy.
Intercurrent infection is recognised as a trigger for CANOMAD
relapse, although there remains limited published data to substanti-
ate this [1]. Hitherto, this is the first reported case of CANOMAD
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relapse associatedwithCOVID-19. Immune-mediated neuropathy and
exacerbations of chronic neuromuscular disease have been described
amongst possible complications of COVID-19 [4,5]. However, other
evidence implies a lack of causality, for example, between COVID-19
and GBS [6]. SARS-CoV-2 has the ability to bind to sialic acid contain-
ing glycoproteins andgangliosidesoften foundonperipheral nerves [7].
Shared glycoprotein epitopesmayhave incited a high degree of specific
immune stimulation, triggering the observed CANOMAD relapse. Pos-
itiveGD1b antibodies in aMiller Fisher syndromepatientwithCOVID-
19may lend support to this theory of immune cross-reactivity between
the SARS-CoV-2 spike and peripheral nerve gangliosides [8]. However,
the specificity of this proposed immune response remains unproven.
Neuropathy is present in up to 31% of patients with IgM mono-
clonal gammopathy and as many as 62.5% of patients withWM [9,10].
As neuropathy may be an indication for treatment in WM, identi-
fication of the underlying aetiology is important. The International
Workshops on WM (IWWM) published recommendations in 2017
including a schematic decision tree for evaluating IgM-associated
peripheral neuropathies [11]. However, a rigid interpretation of this
pathway would only result in testing for ganglioside antibodies along-
side anti-MAG antibodies in patients demonstrating conduction slow-
ing/demyelination on electrophysiological testing. Findings from a
recent large study of 45 patients with CANOMAD revealed a demyeli-
nating pattern in 60%, with predominantly axonal features in 27% [3].
Therefore, it is important not to rely solely on the reported pattern of
electrophysiological abnormality, and maintain a high index of suspi-
cion in cases exhibiting the aforementioned neurological phenotype.
There remains a lack of evidence-base for the treatment of
CANOMAD. IVIg and rituximab are reportedly most efficacious,
whereas corticosteroids and other forms of immunosuppression have
little or unfavourable impact [3]. In this case, rituximab—administered
for the haematological malignancy and associated neuropathy—likely
had a stabilising effect on the neuropathy, in keeping with previously
described cases [3,12].
4 CONCLUSION
Whilst the CANOMAD acronym may prove a useful aide memoir, not
all cases exhibit the full spectrum of clinical features. Craniobulbar
relapses are common and may be precipitated by infection, including
COVID-19. Algorithmic approaches may mislead the diagnostic pro-
cess, and high degree of clinical vigilance is required, with screening for
disialosyl antibodies considered in those with chronic ataxic neuropa-
thy, IgM paraproteinaemia and negative anti-MAG antibodies. Closer
collaboration between haematologists and neurologists is encouraged
to facilitate timely diagnosis and improve clinical outcome.
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